Mereo BioPharma Group plc Price-FCF Ratio
The price-to-free-cash-flow (P/FCF) ratio tells you how many dollars investors pay for each dollar of cash a company generates after paying for its capital spending. It is market capitalization divided by free cash flow over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher ratio means investors are paying more for each dollar of free cash flow; a negative ratio means the company spent more cash than it generated over those quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Mereo BioPharma Group plc price-fcf ratio for the quarter ending 2026-06-30 was -10.44, a change of 55.21 year-over-year.
- Mereo BioPharma Group plc price-fcf ratio for the quarter ending 2026-03-31 was -9.97, a change of 43.92 year-over-year.
- Mereo BioPharma Group plc price-fcf ratio for the quarter ending 2025-12-31 was -10.66, a change of 72.03 year-over-year.
- Mereo BioPharma Group plc price-fcf ratio for the quarter ending 2025-09-30 was -50.07.
- Mereo BioPharma Group plc price-fcf ratio for fiscal 2026 was -10.44.
- Mereo BioPharma Group plc price-fcf ratio for fiscal 2025 was -10.66, a change of 72.03 from fiscal 2024.
- Mereo BioPharma Group plc price-fcf ratio for fiscal 2024 was -82.69.
- Available history
- 2024-12-31 to 2026-06-30
- Data captured
Historical Price-FCF Ratio
Annual Price-FCF Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |